Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer

Registry ID

EUCTR2018-004835-56

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

Grupo español mutidisciplinar en cáncer digestivo (GEMCAD)

Start date

2019-08-13

Last update

2026-08-16

Conditions

• Locally advanced rectal cancer

Summary

Pathological complete response (pCR) rate.

Locations

• , , Spain

View on source registry